At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 491 enrolled
Drug / intervention
CLS006 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Randomized, Double-Blind, Vehicle-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts
In Brief
A Phase 3 clinical trial evaluating CLS006 and CLS006 Vehicle for Cutaneous Common Warts. Completed, enrolled 491 participants across 35 sites.
Detailed Summary
To evaluate the efficacy and safety of six (6) weeks of once daily application of Furosemide Topical Gel 0.125% (CLS006) compared to vehicle in subjects ≥ 2 years of age with nongenital cutaneous common warts (verruca vulgaris).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCutaneous Common Warts
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedAug 2017
Enrollment StartOct 2017
Primary CompletionAug 2018
Study CompletionNov 2018
TodayJul 2026
First PostedAug 23, 2017
Enrollment StartOct 30, 2017
Primary CompletionAug 22, 2018
Study CompletionNov 7, 2018
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 8.9 years ago
Interventions
CLS006drug
Furosemide Topical Gel
CLS006 Vehicledrug
Vehicle Topical Gel